

CERTARA[®]

CODEX Clinical Outcomes Databases

Hidradenitis Suppurativa (HS)



Curated clinical trial data for earlier, confident decisions

Certara's Clinical Trial Outcomes Database (CODEX) is an expertly curated database of clinical trial data for marketed and pipeline drugs, covering 8 therapeutic areas and 70+ indications. It includes structured and unstructured data that can be downloaded and integrated with internal datasets to support modeling and simulation, enabling earlier, more confident drug development decisions.

With CODEX, you can:



Identify the right trial populations

analyze clinical data to identify target populations for new studies.



Improve study design

refine sample size calculations to reduce costs and increase success rates.



Strengthen regulatory strategy

review integrated summaries of safety and efficacy (ISS/ISE) for similar products to inform regulatory approval strategies.



Demonstrate commercial viability

run economic models to generate additional data points that can be used to demonstrate value to payers and in competitive pricing assessments.

Model-based meta-analysis (MBMA)

MBMA leverages CODEX databases and pharmacology models to increase development productivity, quantitatively inform portfolio decisions, and improve clinical trial success. It optimizes trial design, including timing, endpoints, and dosing, as well as competitive landscape assessment. MBMA also bridges across studies, allowing comparison of treatments and patient populations that may not have been evaluated within the same trial.



~43 studies

Key Efficacy and Safety
Endpoints (HiSCR50,
AN count, DLQI, HS-PGA skin
pain responder, IHS4 score)



~7,540 patients

All systematic or novel
pharmacological treatments



~15,187

Longitudinal Data Points
- Format available in Excel and
CODEX (Clinical Outcome
Database Explorer)

A comprehensive repository of HS clinical outcomes

The CODEX Hidradenitis Suppurativa (HS) Database provides utility across the drug development continuum to inform critical decisions that determine not only a drug’s successful performance during a trial, but also a drug’s profile within a competitive landscape. The HS database highlighted here is curated to document clinical safety and efficacy information from all randomized placebo and active controlled trials in Hidradenitis Suppurativa patients. Trials found in this database also include washout designs and add on designs.

Treatment	Class	Studies
adalimumab	anti-TNF	7
bimekizumab	anti-IL-17	3
bermekimab	anti-IL-1a	2
clindamycin	antibiotic	2
izokibep	anti-IL-17	2
povorcitinib	JAK1 inhibitor	2
secukinumab	anti-IL-17a	2

Table 1. The top 7 drugs in the CODEX HS database




Figure 1. Snapshot of select treatments

Discover how CODEX can empower more confident decisions.

To learn more or request a demo, visit certara.com/codex

About Certara

Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.